NCT05394246

Fluorescent-labeled IgG for Liver Tumor Detection

Intraoperative Liver Tumor Imaging Using Fluorescent-labeled Human IgG

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Chinese Academy of Sciences · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma). The main purposes of this study include: * To validate the safety and effectiveness of using FluoAB in hepatic surgery. * To raise the surgical precision with guidance by FluoAB fluorescence imaging.

Conditions

• Liver Cancer

Interventions

Type	Name	Description
DRUG	FluoAB	Drug Injection: FluoAB (fluorescent-labeled IgG)

Timeline

• Start date: 2022-05-20
• Primary completion: 2024-12-31
• Completion: 2025-06-30
• First posted: 2022-05-27
• Last updated: 2023-08-30

Locations

1 site across 1 country: China